Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer

New England Journal of Medicine

Volumn 311, Issue 20, 1984, Pages 1281-1286

  Herbst, A L ^a   Garnick, M D ^a   Michael, L ^b   Glode, M D ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ANDROSTANOLONE; DIETHYLSTILBESTROL; LEUPRORELIN; TESTOSTERONE;

ACID PHOSPHATASE BLOOD LEVEL; ADVERSE DRUG REACTION; BREAST; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMPARISON; DRUG EFFICACY; DRUG THERAPY; EDEMA; ENDOCRINE SYSTEM; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; INTOXICATION; MAJOR CLINICAL STUDY; MALE GENITAL SYSTEM; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SERUM; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; THERAPY; THROMBOEMBOLISM; VOMITING;

ACID PHOSPHATASE; ADULT; AGED; ANTINEOPLASTIC AGENTS; DIETHYLSTILBESTROL; DRUG EVALUATION; GONADOTROPIN-RELEASING HORMONE; HORMONES; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RANDOM ALLOCATION;

EID: 0021721387     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198411153112004     Document Type: Article

References (32)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–7.
2. Huggins C, Stevens RE Jr, Hodges CV. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209–23.
3. Huggins C, Scon WW, Hodges CV. Studies on prostatic cancer. III. The effects of fever, of desoxyconicosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate. J Urol 1941; 46: 997–1006.
4. Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 1978; 202: 631–3.
5. Linde R, Doelle GC, Alexander N, Kirchner F, Vale W, Rivier J, Rabin D. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med 1981; 305: 663–7.
6. Berquist C, Nillius SJ, Wide L. Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent. Lancet 1979; 2: 215–7.
7. Labrie F, Cusan L, Séguin C, et al. Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man. Int J Fertil 1980; 25: 157–70.
8. Comite F, Cutler GB Jr, Rivier J, Vale WW, Loriaux DL, Crowley WF Jr. Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone: a preliminary report. N Engl J Med 1981; 305: 1546–50.
9. Crowley WF Jr, Comite F, Vale W, Rivier J, Loriaux DL, Cutler GB Jr. Therapeutic use of pituitary desensitization with a long-acting LHRH agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1980; 52: 370–2.
10. Ahmed SR, Brooman PJC, Shalet SM, Howell A, Blacklock NJ, Rickards D. Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet 1983; 2: 415–9.
11. Walker KJ, Nicholson RI, Turkes AO, et al. Therapeutic potential of the LHRH agonist. ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet 1983; 2: 413–5.
12. Koutsilieris M, Tolis G. Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma. Prostate 1983; 4: 569–77.
13. Allen JM, O'Shea JP, Mashiter K, Williams G, Bloom SR. Advanced carcinoma of the prostate: treatment with a gonadotropin releasing hormone agonist. Br Med J 1983; 286: 1607–9.
14. Waxman JH, Wass JAH, Hendry WF, et al. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J 1983; 286: 1309–12.
15. Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 1983; 4: 579–94.
16. Faure N, Lemay A, Laroche B, et al. Preliminary results on the clinical efficacy and safety of androgen inhibition by the LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma. Prostate 1983; 4: 601–24.
17. Borgmann V, Hardt W, Schmidt-Gollwitzer M, Adenauer H, Nagel R. Sustained suppression of testosterone production by the luteinizing-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma: a new therapeutic approach? Lancet 1982; 1: 1097–9.
18. Glode LM, Max D. Leuprolide (D-leu-6Des Gly10–Pro9-NH Et-LHRH) in the therapy of advanced prostatic cancer. Presented at the 13th international Congress of Chemotherapy, Vienna, Austria, August 28-September 2, 1983.
19. Borgmann V, Nagel R, Al-Abadi H, Schmidt-Gollwitzer M. Treatment of prostatic cancer with LH-RH analogues. Prostate 1983; 4: 553–68.
20. Schmidt JD, Scott WW, Gibbons R, et al. Chemotherapy programs of the National Prostatic Cancer Project. Cancer 1980; 45: 1937–46.
21. Blum JJ, Conn PM. Gonadotropin-releasing hormone stimulation of luteinizing hormone release: a ligand–receptor–effector model. Proc Natl Acad Sci USA 1982; 79: 7307–311.
22. Smith WA, Conn PM. GnRH-mediated desensitization of the pituitary gonadotrope is not calcium dependent. Endocrinology 1983; 112: 408–10.
23. Redding TW, Schally AV. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1981; 78: 6509–12.
24. Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 1982; 79: 1658–62.
25. Warner B, Worgul TJ, Drago J, et al. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. Clin Invest 1983; 71: 1842–53.
26. Santen RJ, Demers LM, Max DT, Smith J, Stein BS, Glode LM. Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma. J Clin Endocrinol Metab 1984; 58: 397–400.
27. Winfield H, Trachtenberg J. A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer. J Urol 1984; 131: 1107–9.
28. Blackard CE, Byar DP, Jordan WP Jr. Orchiectomy for advanced prostatic carcinoma: a reevaluation. Urology 1973; 1: 553–60.
29. Byar DP. VACURG studies of conservative treatment. Scand J Urol Nephrol [Suppl] 1980; 55: 99–102.
30. Bailar JC III, Byar DP, Veterans Administration Cooperative Urological Research Group. Estrogen treatment for cancer of the prostate: early results with 3 doses of diethylstilbestrol and placebo. Cancer 1970; 26: 257–61.
31. Robinson MRG, Thomas BS. Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br Med J 1971; 4: 391–4.
32. Smith PH. Endocrine and cytotoxic therapy. Recent Results Cancer Res 1981; 78: 154–72.